Uncovering the natural history of prostate cancer

Mar 17, 2021 | Press Release

Uncovering the natural history of prostate cancer

Mar 17, 2021 | Press Release

Prostate cancer: clinicians and researchers join forces

Clinicians and researchers are joining forces in a virtual studyathon to explore the natural history of prostate cancer in a large dataset of patients from across the globe. Clinicians, epidemiologists and other researchers are invited to take part.

The aim is to:

– study the clinical management of prostate cancer.
– support clinicians and researchers with better data on the possible outcomes of different treatment options.
– explore the potential to generate and validate more accurate prediction algorithms based on data from Europe, the USA and other parts of the globe.

Prostate cancer is a major disease affecting more than 2 million men in Europe alone, and has now become the most common cancer in men. Clinical management of this complex disease is challenging and involves difficult trade-offs, since in reality prostate cancer consists of a spectrum of diseases ranging from low-risk to very aggressive forms. Therefore, doctors and patients have to make difficult decisions on how to treat the disease and in some case on whether or not to treat the disease, which also involves risk.

Unfortunately, there is still surprisingly little data at scale on what the ‘natural history’ (progression of the disease in absence of treatment) is and how co-morbidities (other life-threatening medical conditions) influence the life expectancy of patients diagnosed with prostate cancer. It would greatly aid shared-decision making between clinicians and patients to have a better understanding of which patients will pass away as a result of prostate cancer versus other causes, to establish where treatment would be most effective and to avoid unnecessary interventions for patients.

Joint forces to study the clinical management of prostate cancer

To achieve this clinicians and researchers are joining forces in a virtual studyathon to explore the natural history of prostate cancer in a large dataset of patients from across the globe. The aim of the studyathon is to support clinicians and researchers with better data on the possible outcomes of different treatment options and to explore the potential to generate and validate more accurate prediction algorithms based on data from Europe, the USA and other parts of the globe.

New big data approaches pioneered by OHDSI and EHDEN are changing the way in which medical evidence is generated through systematic large-scale data analysis in health data sources globally. In particular, a studyathon is a focused event in which a large-scale study, which traditionally takes many months to complete, is executed and completed in a few days. This approach has recently been successfully applied to studies in rheumatoid arthritis, hypertension and COVID-19 (see links below), and we now aim to do the same for prostate cancer. Movember is supporting this project too with project design ideas drawn from their experiences in multidisciplinary, global collaboration.

Via PIONEER and EHDEN, datasets with healthcare records for more than 1 million patients with prostate cancer are already accessible for the studyathon, but we are seeking additional data sources with longitudinal data, especially those converted to the OMOP Common Data Model to join this effort. Clinicians, epidemiologists and other researchers interested in this question are also invited to take part.
The studyathon itself will be a five day virtual event on 8-12 March 2021, with sessions every day focused on literature review, phenotype definition, analytics and results interpretation, and will follow the OHDSI approach. Please register your interest via this link and join us in this journey!

The projects

PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope) is a European project focused on using big data to improve the clinical understanding and inform the diagnosis and treatment of prostate cancer, funded through IMI2 JU, and is listed under grant agreement No. 777492.

EHDEN (European Health Data & Evidence Network) is a European project focused on generating medical insights at scale from real-world clinical data, funded through IMI2 JU, and is listed under grant agreement No. 806968.

OHDSI (Observational Health Data Sciences and Informatics) is a multi-stakeholder, interdisciplinary open science collaborative aiming to bring out the value of health data through large-scale analytics. Earlier studyathons have resulted in publications in amongst others The Lancet Rheumatology, The Lancet Digital Health and Nature Communications.

PIONEER and EHDEN are funded through the IMI2 Joint Undertaking. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

(Senior) Funding Consultant (m/f/d)

(Senior) Funding Consultant (m/f/d)

We offer you the unique opportunity to become part of a new team in the attractive growing market for tax-based research funding - Research Allowance Act (FZulG). ARTTIC Innovation GmbH opens a new office in Bonn, or you can work at the headquarters in Munich. We are...

read more
SUN-to-LIQUID Demonstration Event

SUN-to-LIQUID Demonstration Event

Over the last 3.5 years, the SUN-to-LIQUID project has built a unique research facility to demonstrate the thermochemical synthesis of liquid hydrocarbon fuels from water, carbon dioxide and high-flux solar radiation. To showcase this achievement, the SUN-to-LIQUID...

read more
R&D Sales Consultant (m/f/d)

R&D Sales Consultant (m/f/d)

Become part of Europe's leading funding & innovation consultancy! We offer you the unique opportunity to become part of a new team in the attractive growing market for tax-based research funding - Research Allowance Act (FZulG). ARTTIC Innovation GmbH opens a new...

read more
Personnel: ARTTIC Innovation grows

Personnel: ARTTIC Innovation grows

Already in the first quarter of 2021 Arttic Innovation is supporting its clients in more than 100 research projects to apply for fundings from the Research Grants Act (fzugl.eu).ARTTIC has expanded its consultant team with Dr. Julia Tschirka, Daniel Pawliczek and...

read more